Published in PLoS One on November 11, 2013
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis (2016) 1.17
Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication. Viruses (2015) 1.10
Editorial commentary: Comparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohorts. Clin Infect Dis (2014) 1.09
Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know? J Int AIDS Soc (2016) 0.86
Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. Clin Infect Dis (2015) 0.78
Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. Infect Dis Ther (2016) 0.76
An enhanced Emtricitabine loaded long-acting nano-formulation for prevention or treatment of HIV infection. Antimicrob Agents Chemother (2016) 0.75
Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations. Patient Prefer Adherence (2015) 0.75
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis. Colomb Med (Cali) (2017) 0.75
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
The statistical basis of meta-analysis. Stat Methods Med Res (1993) 6.87
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol (2011) 3.30
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr (2010) 2.85
GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol (2011) 2.83
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med (2012) 2.40
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr (2006) 2.17
Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem (1992) 2.13
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12
The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther (2004) 1.43
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA (2004) 1.42
Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother (1994) 1.33
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr (2009) 1.28
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr (2009) 1.16
A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS (2004) 1.14
Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr (2003) 1.11
Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis (2012) 1.08
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis (2013) 0.99
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials (2008) 0.90
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr (2011) 0.85
Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS (2009) 0.84
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis (2008) 0.81
Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retroviruses (2012) 0.81
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med (2013) 0.81
Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities. Int J Antimicrob Agents (2012) 0.79
Cost-effectiveness of generic antiretroviral therapy--in response. Ann Intern Med (2013) 0.78
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet (2010) 12.92
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet (2006) 11.06
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
25 years of the WHO essential medicines lists: progress and challenges. Lancet (2003) 4.95
Current status and future prospects of epidemiology and public health training and research in the WHO African region. Int J Epidemiol (2012) 3.60
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med (2005) 3.27
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis (2008) 3.15
Treatment of periodontal disease for glycaemic control in people with diabetes. Cochrane Database Syst Rev (2010) 3.08
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS (2006) 2.82
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Shortages of medicines: a complex global challenge. Bull World Health Organ (2012) 2.60
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS (2010) 2.51
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med (2008) 2.44
Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One (2012) 2.39
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet (2009) 2.35
History, principles, and practice of health and human rights. Lancet (2007) 2.19
Ramping up biodiversity discovery via online quantum contributions. Trends Ecol Evol (2011) 2.15
Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. Trop Med Int Health (2012) 2.08
The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy. PLoS One (2012) 2.05
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS (2012) 2.03
Starter packs versus full prescription of antiretroviral drugs for postexposure prophylaxis: a systematic review. Clin Infect Dis (2015) 2.02
Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav (2012) 2.01
A new fossil thryonomyid from the Late Miocene of the United Arab Emirates and the origin of African cane rats. Naturwissenschaften (2013) 1.98
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Biodiversity informatics: automated approaches for documenting global biodiversity patterns and processes. Bioinformatics (2009) 1.94
Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS (2007) 1.94
Teaching practicing surgeons critical appraisal skills with an Internet-based journal club: A randomized, controlled trial. Surgery (2004) 1.93
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93
The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials (2009) 1.92
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ (2009) 1.91
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet (2006) 1.91
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health (2006) 1.91
Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS (2010) 1.88
Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ (2012) 1.85
Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. AIDS Res Hum Retroviruses (2010) 1.84
Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS (2010) 1.83
Neglected diseases, civil conflicts, and the right to health. Lancet (2007) 1.80
Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int (2011) 1.75
Iraq War mortality estimates: a systematic review. Confl Health (2008) 1.72
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS (2014) 1.67
Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ Open (2013) 1.66
Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS (2011) 1.61
Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend (2007) 1.60
New WHO HIV treatment and prevention guidelines. Lancet (2009) 1.59
40Ar/(39)Ar geochronology and paleomagnetic stratigraphy of the Lukeino and lower Chemeron Formations at Tabarin and Kapcheberek, Tugen Hills, Kenya. J Hum Evol (2002) 1.56
Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One (2011) 1.56
Sharing evidence on humanitarian relief. BMJ (2005) 1.56
Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. PLoS One (2014) 1.55
Barriers to the effective treatment and prevention of malaria in Africa: A systematic review of qualitative studies. BMC Int Health Hum Rights (2009) 1.54
HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets (2011) 1.53
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis (2005) 1.52
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Safety of task-shifting for male medical circumcision: a systematic review and meta-analysis. AIDS (2012) 1.51
Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc (2010) 1.51
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS (2013) 1.49
Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis. PLoS One (2011) 1.48
Large calibre arterial access device closure for percutaneous aortic valve interventions: use of the Prostar system in 118 cases. Catheter Cardiovasc Interv (2011) 1.47
Health system determinants of infant, child and maternal mortality: A cross-sectional study of UN member countries. Global Health (2011) 1.46
Magnetic resonance imaging of the common bile duct to exclude choledocholithiasis. ANZ J Surg (2004) 1.43
Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther (2004) 1.43
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. HIV Clin Trials (2009) 1.42
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS (2010) 1.41
Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles? AIDS (2005) 1.40
Initial experience with the Ventana fenestrated system for endovascular repair of juxtarenal and pararenal aortic aneurysms. J Vasc Surg (2013) 1.38
Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS (2008) 1.35
Ethics of conducting research in conflict settings. Confl Health (2009) 1.34
HIV/AIDS in African militaries: an ecological analysis. Med Confl Surviv (2008) 1.34
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda. J Hypertens (2013) 1.33
LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact. Trials (2009) 1.32
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol (2007) 1.30
Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis (2012) 1.30
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. J Antimicrob Chemother (2008) 1.29
The first decade of antiretroviral therapy in Africa. Global Health (2011) 1.27
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS (2004) 1.26
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol (2005) 1.26
Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J (2005) 1.26
In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med (2008) 1.26
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis (2003) 1.25
Aging with HIV in Africa: the challenges of living longer. AIDS (2012) 1.21
Plasma membrane recruitment and activation of the AGC kinase Ypk1 is mediated by target of rapamycin complex 2 (TORC2) and its effector proteins Slm1 and Slm2. Proc Natl Acad Sci U S A (2012) 1.21